Trowbridge Stephen A
Known title: EVP and CFOCIK: 0001624250
Trowbridge Stephen A's purchase track record
How the stock did after each of Trowbridge Stephen A's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since January 12, 2022
Stock higher 6 months later
25%
3 months: 50%
Median 6-month return
-6.6%
3 months: -0.2%
Beat the S&P 500
50%
median +1.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/13/2025 | ANGO | $10K | -8.5% | -8.0% | +3.5% |
| 10/8/2024 | ANGO | $10K | +59.9% | +53.1% | -13.4% |
| 10/12/2022 | ANGO | $15K | -5.1% | -34.4% | +14.4% |
| 1/12/2022 | ANGO | $23K | +4.8% | -5.3% | -19.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ANGO | ▲ Buy | Option Exercise | 16,296 | $0 | 7/22/2026 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 8,319 | $115K | 7/22/2026 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 717 | $10K | 7/20/2026 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 3,510 | $47K | 7/17/2026 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 7,840 | $111K | 7/16/2026 | View on chart |
| ANGO | ▲ Buy | Grant | 53,257 | $0 | 7/15/2026 | View on chart |
| ANGO | ▲ Buy | Open Market | 890 | $10K | 10/13/2025 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 667 | $6K | 7/21/2025 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 717 | $6K | 7/20/2025 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 2,585 | $22K | 7/19/2025 | View on chart |
| ANGO | ▲ Buy | Grant | 86,997 | $0 | 7/16/2025 | View on chart |
| ANGO | ▲ Buy | Open Market | 1,700 | $10K | 10/8/2024 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 667 | $5K | 7/21/2024 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 717 | $5K | 7/20/2024 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 2,585 | $19K | 7/19/2024 | View on chart |
| ANGO | ▲ Buy | Grant | 38,953 | $0 | 7/17/2024 | View on chart |
| ANGO | ▲ Buy | Option Exercise | 11,142 | $0 | 7/17/2024 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 4,016 | $30K | 7/17/2024 | View on chart |
| ANGO | ▲ Buy | Grant | 1,927 | $9K | 2/29/2024 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 667 | $6K | 7/21/2023 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 717 | $6K | 7/20/2023 | View on chart |
| ANGO | ▲ Buy | Option Exercise | 8,769 | $0 | 7/19/2023 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 3,159 | $28K | 7/19/2023 | View on chart |
| ANGO | ▲ Buy | Grant | 28,691 | $0 | 7/19/2023 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 376 | $4K | 7/17/2023 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 1,362 | $13K | 7/14/2023 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 555 | $7K | 2/3/2023 | View on chart |
| ANGO | ▲ Buy | Open Market | 1,083 | $15K | 10/12/2022 | View on chart |
| ANGO | ▲ Buy | Grant | 7,961 | $0 | 7/20/2022 | View on chart |
| ANGO | ▲ Buy | Option Exercise | 14,758 | $235K | 7/15/2022 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 12,398 | $264K | 7/15/2022 | View on chart |
| ANGO | ▲ Buy | Option Exercise | 4,188 | $0 | 7/7/2022 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 1,509 | $31K | 7/7/2022 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 583 | $12K | 2/3/2022 | View on chart |
| ANGO | ▲ Buy | Open Market | 1,000 | $23K | 1/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ANGO Announces Q1 Fiscal 2027 Results Date
AngioDynamics (ANGO) will report its fiscal 2027 first‑quarter earnings on Oct. 8, 2026. The earnings release will provide updated guidance on revenue, operating income and cash flow for the quarter. Analysts will review the results to assess the company’s performance against expectations. The announcement is the main event for the stock this week.
ANGO Announces Q1 Fiscal 2027 Results Date. AngioDynamics (ANGO) will report its fiscal 2027 first‑quarter earnings on Oct. 8, 2026. The earnings release will provide updated guidance on revenue, operating income and cash flow for the quarter. Analysts will review the results to assess the company’s performance against expectations. The announcement is the main event for the stock this week.